Trial Profile
A phase 2 proof of concept study with ANS-6637 as an aide to Smoking Cessation
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 25 Nov 2019
Price :
$35
*
At a glance
- Drugs ANS 6637 (Primary)
- Indications Smoking withdrawal
- Focus Proof of concept; Therapeutic Use
- Sponsors Amygdala Neurosciences
- 18 Nov 2019 According to an Amygdala Neurosciences media release, the company has secured $5.6M financing which will be used to fund this trial.
- 17 Oct 2019 According to an Amygdala Neurosciences media release, this study is planned to initiate early next year.
- 04 Apr 2019 New trial record